The only long-term preventative treatment for HAE attacks with a tested guide to support switching safely

The safety and efficacy of DAWNZERA were evaluated in the primary study. Across 6 months, those who took DAWNZERA every 4 weeks saw 81% fewer attacks on average vs placebo (primary endpoint). The most common side effects of DAWNZERA include injection-site reactions (such as redness or pain at the injection site), upper respiratory tract infection, urinary tract infection, and abdominal discomfort. Learn more about the safety of DAWNZERA.

In the open-label study, DAWNZERA was evaluated in people who switched from lanadelumab, berotralstat, or a C1-INH.

Across 1 year, people safely and successfully switched to DAWNZERA with no average loss of efficacy.

Hereditary angioedema (HAE) attack reduction was seen regardless of prior preventative treatment.*

9 out of 10 people

 in the study who used the Angioedema Control Test (AECT) reported being well-controlled after switching to DAWNZERA (exploratory endpoint interim analyses at Week 16 and Week 52).

84%

of people surveyed in an interim analysis after 16 weeks of treatment preferred DAWNZERA over their previous preventative treatment, citing better disease control, less time required for treatment, and reduced injection pain as reasons for their preference.

These are not head-to-head data. Results are from an open-label, uncontrolled safety study in patients who wanted to switch to DAWNZERA, and was not powered for any comparisons between prior treatment groups; thus, these observations cannot be generalized to other patients on prior long-term preventative treatments.

C1-INH=C1-inhibitor.

*Previous on-treatment monthly HAE attack rate established in the 10-week screening period.

The AECT is a simple, 4 question survey that helps you and your doctor understand how well your swelling symptoms have been managed over the past month.

More than 1 reason was permitted. Exploratory endpoint interim analysis at Week 16.

Hear from a person who switched to DAWNZERA

Watch Lindsey and Lauren's story to learn about their DAWNZERA™ journeys

Actual DAWNZERA patients. Patients were compensated for their time.


Dosing done differently

Medical shield icon.

NO loading dose

Begin treatment with a single injection, right from the start

Autoinjector icon.

NO mixing or syringes

A convenient, single-use autoinjector§

Icon of calendar with an autoinjector.

NO daily medicine reminders

Dosing once every 4 weeks or every 8 weeks

§DAWNZERA autoinjectors can be stored in its original carton at room temperature (up to 86 °F [30 °C]) for up to 6 weeks. Do not expose your DAWNZERA autoinjector to heat, do not freeze it, and protect it from direct light.

Patient Education Managers cannot give medical advice and do not replace your medical team. Contact your doctor for any medical concerns.